Surgery Partners (SGRY) to Release Quarterly Earnings on Tuesday

Surgery Partners (NASDAQ:SGRY) is expected to issue its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $797.6880 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.44 earnings per share. On average, analysts expect Surgery Partners to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Surgery Partners Stock Performance

SGRY opened at $14.27 on Friday. The company has a quick ratio of 1.71, a current ratio of 1.87 and a debt-to-equity ratio of 1.15. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -23.02 and a beta of 1.99. Surgery Partners has a 52-week low of $11.41 and a 52-week high of $24.18. The firm’s fifty day simple moving average is $13.39 and its two-hundred day simple moving average is $15.68.

Surgery Partners declared that its board has initiated a stock buyback plan on Thursday, February 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 9.7% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at Surgery Partners

In other news, insider Jennifer Baldock sold 10,082 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $13.70, for a total value of $138,123.40. Following the transaction, the insider directly owned 332,272 shares of the company’s stock, valued at approximately $4,552,126.40. This trade represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO David T. Doherty sold 14,574 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $13.84, for a total transaction of $201,704.16. Following the completion of the transaction, the chief financial officer directly owned 88,803 shares in the company, valued at approximately $1,229,033.52. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 96,896 shares of company stock valued at $1,284,058. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Surgery Partners

A number of institutional investors have recently made changes to their positions in SGRY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Surgery Partners by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,693 shares of the company’s stock valued at $1,085,000 after acquiring an additional 2,015 shares during the last quarter. Millennium Management LLC increased its position in shares of Surgery Partners by 1,253.7% during the first quarter. Millennium Management LLC now owns 202,274 shares of the company’s stock valued at $4,804,000 after acquiring an additional 219,806 shares during the last quarter. Empowered Funds LLC increased its position in shares of Surgery Partners by 11.0% during the first quarter. Empowered Funds LLC now owns 12,853 shares of the company’s stock valued at $305,000 after acquiring an additional 1,278 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Surgery Partners during the second quarter valued at about $219,000. Finally, Invesco Ltd. increased its position in shares of Surgery Partners by 7.4% during the second quarter. Invesco Ltd. now owns 1,683,311 shares of the company’s stock valued at $37,420,000 after acquiring an additional 115,627 shares during the last quarter.

Analyst Upgrades and Downgrades

SGRY has been the topic of several recent analyst reports. Barclays decreased their price objective on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 3rd. Benchmark reaffirmed a “buy” rating on shares of Surgery Partners in a report on Tuesday, March 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Surgery Partners in a report on Wednesday, March 4th. Royal Bank Of Canada decreased their price target on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 4th. Finally, Mizuho decreased their price target on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Surgery Partners has an average rating of “Moderate Buy” and an average price target of $22.00.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.